Janelle Fauci, MD
Gynecologic Oncology · Charlotte, NCNPI 1144423542
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.7%), food and beverage and education — rather than concentrated in one kind of arrangement. AbbVie accounts for 62.6% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $2,557, more than ten times the $32 reported in 2020.
Across 21 payments — averaging $199.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Biotissue Holdings Inc.$644
- AstraZeneca$355
- GSK$186
- Myriad Genetic Laboratories, Inc.$118
- Immunogen, Inc.$117
- plus $148 from 2 others
Across 137 payments — averaging $19,434 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$1.7M
- Tesaro, Inc.$424K
- Genentech, Inc.$310K
- Merck$204K
- AstraZeneca$45K
What the payments were for
- Speaking & faculty fees$2,37557%
- Food & beverage$1,62839%
- Education$1864%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 3 | $2,621 |
| Biotissue Holdings Inc. | 7 | $644 |
| AstraZeneca | 4 | $355 |
| GSK | 3 | $186 |
| Myriad Genetic Laboratories, Inc. | 1 | $118 |
| Immunogen, Inc. | 1 | $117 |
| Astellas Pharma US Inc | 1 | $116 |
| Intuitive Surgical | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,189 in reported general payments places this provider in the 65th percentile of 52 gynecologic oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 61 | $445 |
| Oxycodone Hcl | 55 | $226 |
| Ibuprofen | 52 | $187 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Charlotte
- Robert NaumannCharlotte$221K
- Erin CraneCharlotte$98K
- Jubilee BrownCharlotte$44K
- John McDonaldCharlotte$11K
- Kellie SchneiderCharlotte$7K
- David TaitCharlotte$2K
- Malcolm RossCharlotte$1K
- Brittany LeesCharlotte$427
- Lucybeth Nieves ArribaWilmington$251K
- Angeles SecordDurham$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.